The Future of Genetics-led Cancer Therapeutics
A key advance in the fight against cancer is the availability of multiple treatment modalities developed to target different aspects of tumourigenesis and maintenance of cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The ESMO Daily Reporter is the official ESMO Congress newspaper, providing expert perspectives on controversial topics and session highlights, with live reporting and critical insights on data.
Lectures from this year’s ESMO awards recipients kick off the week leading up to the Education weekend of the ESMO Virtual Congress 2020
A key advance in the fight against cancer is the availability of multiple treatment modalities developed to target different aspects of tumourigenesis and maintenance of cancer
The current evidence suggests that a large proportion of patients not responding to PD-1/PD-L1-targeted agents do not have PD-L1-expressing tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
Analytics cookies help us improve our website by collecting and reporting information on its usage.
We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.